-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Kyntra Bio, Lowers Price Target to $30

Benzinga·11/17/2026 14:18:04
Oppenheimer analyst Jay Olson maintains Kyntra Bio (NASDAQ:KYNB) with a Outperform and lowers the price target from $35 to $30.